Literature DB >> 15705859

Deregulated estrogen receptor alpha expression in mammary epithelial cells of transgenic mice results in the development of ductal carcinoma in situ.

M Silvina Frech1, Ewa D Halama, Maddalena T Tilli, Baljit Singh, Edward J Gunther, Lewis A Chodosh, Jodi A Flaws, Priscilla A Furth.   

Abstract

A conditional tetracycline-responsive transgenic mouse model with deregulated estrogen receptor alpha expression in mammary epithelial cells developed ductal hyperplasia (DH), lobular hyperplasia, and ductal carcinoma in situ (DCIS) by 4 months of age. Higher proliferative rates were found in both normal and abnormal ductal and lobular structures. DH and DCIS but not normal ductal structures showed an increased percentage of cells with nuclear-localized cyclin D1. No differences in either the prevalence or extent of these phenotypes following exogenous 17beta-estradiol treatment were found suggesting that alteration of ERalpha expression was the rate-limiting factor in initiation of DH, lobular hyperplasia, and DCIS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15705859      PMCID: PMC6952528     

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

Review 1.  Intrinsic and Extrinsic Factors Governing the Transcriptional Regulation of ESR1.

Authors:  David K Lung; Rebecca M Reese; Elaine T Alarid
Journal:  Horm Cancer       Date:  2020-06-26       Impact factor: 3.869

2.  Hormone-responsive 3D multicellular culture model of human breast tissue.

Authors:  Xiuli Wang; David L Kaplan
Journal:  Biomaterials       Date:  2012-02-04       Impact factor: 12.479

Review 3.  Illuminating the center: mechanisms regulating lumen formation and maintenance in mammary morphogenesis.

Authors:  Mauricio J Reginato; Senthil K Muthuswamy
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-10       Impact factor: 2.673

4.  Alterations of gene expression in the development of early hyperplastic precursors of breast cancer.

Authors:  Sangjun Lee; Dan Medina; Anna Tsimelzon; Syed K Mohsin; Sufeng Mao; Yun Wu; D Craig Allred
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

5.  Accelerated mammary maturation and differentiation, and delayed MMTVneu-induced tumorigenesis of K303R mutant ERalpha transgenic mice.

Authors:  M H Herynk; M T Lewis; T A Hopp; D Medina; A Corona-Rodriguez; Y Cui; A R Beyer; S A W Fuqua
Journal:  Oncogene       Date:  2009-06-29       Impact factor: 9.867

6.  Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor alpha gene expression via p38MAPK/CK2 signaling in human breast cancer cells.

Authors:  Francesca De Amicis; Francesca Giordano; Adele Vivacqua; Michele Pellegrino; Maria Luisa Panno; Donatella Tramontano; Suzanne A W Fuqua; Sebastiano Andò
Journal:  FASEB J       Date:  2011-07-07       Impact factor: 5.191

7.  In vitro mechanism for downregulation of ER-α expression by epigallocatechin gallate in ER+/PR+ human breast cancer cells.

Authors:  Francesca De Amicis; Alessandra Russo; Paola Avena; Marta Santoro; Adele Vivacqua; Daniela Bonofiglio; Loredana Mauro; Saveria Aquila; Donatella Tramontano; Suzanne A W Fuqua; Sebastiano Andò
Journal:  Mol Nutr Food Res       Date:  2013-01-16       Impact factor: 5.914

8.  The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells.

Authors:  Yongxian Ma; Pragati Katiyar; Laundette P Jones; Saijun Fan; Yiyu Zhang; Priscilla A Furth; Eliot M Rosen
Journal:  Mol Endocrinol       Date:  2005-08-18

9.  Prolactin drives estrogen receptor-alpha-dependent ductal expansion and synergizes with transforming growth factor-alpha to induce mammary tumors in males.

Authors:  Lisa M Arendt; Linda A Schuler
Journal:  Am J Pathol       Date:  2007-12-21       Impact factor: 4.307

10.  Repression of ESR1 through actions of estrogen receptor alpha and Sin3A at the proximal promoter.

Authors:  Stephanie J Ellison-Zelski; Natalia M Solodin; Elaine T Alarid
Journal:  Mol Cell Biol       Date:  2009-07-20       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.